4 April 2025
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Notice of Results and Investor Presentation
Proteome Sciences (AIM: PRM) announces that the Company's results for the year ending 31 December 2024 will be announced on 10 April 2025 (the "Final Results"). The Company looks forward to updating shareholders on the Company's performance and on the outlook for 2025.
On the 11 April 2025 at 10:30 BST the Company's Executive Chairman, Christopher Pearce and Dr Ian Pike, the Chief Scientific Officer (CSO), will provide a live presentation relating to the Final Results via Investor Meet Company.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 10 April 2025, 09:00 BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Proteome Sciences via: https://www.investormeetcompany.com/proteome-sciences-plc/register-investor
Investors who already follow Proteome Sciences on the Investor Meet Company platform will automatically be invited.
For further information please contact:
| Proteome Sciences plc | |||
| Dr. Ian Pike, Chief Scientific Officer | Tel: +44 (0)20 7043 2116 |
| |
| Richard Dennis, Chief Commercial Officer
|
|
| |
| Allenby Capital Limited (Nominated Adviser & Broker) |
| ||
| John Depasquale/Lauren Wright (Corporate Finance) Tony Quirke/Stefano Aquilino (Equity Sales & Corporate Broking)
| Tel: +44 (0) 20 3328 5656 |
| |
|
| |||
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.